| ²é¿´: 2775 | »Ø¸´: 7 | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
mouse103ר¼Ò¹ËÎÊ (ÖøÃûдÊÖ)
|
[½»Á÷]
Å·ÖÞÒ©µä¶ÔÔÁÏÒ©ÖлÇËáõ¥Àà»ùÒòÔÓÖʵÄÎå¸öÐÂͨÔò ÒÑÓÐ6È˲ÎÓë
|
||
|
ÒÔÏÂÊÇÅ·ÖÞÒ©µä¶ÔÔÁÏÒ©ÖлùÒòÔÓÖʵÄÎå¸öÐÂͨÔò£¬Í¨¹ýÖÐÎÄ·Òë·ÖÏí¸ø³æÓÑ£¬ÈçÓв»µ±»¶ÓÖ¸Õý¡£Í¬Ê±Ï£ÍûÄÄλ³æÓÑÄÜ·ÖÏíEP8.7ÖиÃÄÚÈݵÄÎå¸ö׍ָ¡£ÆÚ´ý£¡ Å·ÖÞÒ©µä¶ÔÔÁÏÒ©ÖлùÒòÔÓÖʵÄÎå¸öÐÂͨÔò £¨Five new General Chapters in the European Pharmacopoeia on Genotoxic Impurities in Pharmaceutical APIs£© »ÇËá¾³£ÓÃÓÚÔÁÏÒ©µÄÉú²úÖС£»ÇËá¿ÉÄÜÓÃÔÚ³ÉÑιý³Ì£¬ÔÁÏÒ©ºÏ³ÉÖл»ùÍÅ»òËá´ß»¯¡£¹¤ÒÕÖÐÈç¹ûÓõ½¶ÌÁ´´¼£¬Èç¼×´¼¡¢ÒÒ´¼»òÒì±û´¼£¬Ôò¿ÉÄÜ»áºÍ»ÇËáÉú³É»ÇËáõ¥¡£ËüÃÇ¿ÉÄÜÓÐDZÔÚ»ùÒò¶¾ÐÔ£¨DNAÍé»ù»¯£©¡£ Sulfonic acids are often used for the manufacture of pharmaceutical APIs. They serve as counterions in crystallisation processes, as protective groups or acid catalysts in API syntheses. Here, if short-chain alcohols such as methanol, ethanol or isopropanol are present, the formation of esters of these sulfonic acids can occur, which may have a genotoxic potential (alkylation of DNA). 2008ÄêÅ·ÃËÒ©µäίԱ»á³ÉÁ¢Á˼׻ÇËáÑι¤×÷×飬ÄⶨÁË5¸ö²»Í¬»ÇËáÎïµÄͨÔò£¬ÕâЩͨÔòÔÚEPÔö²¹8.7Öй«²¼£¬½«×Ô2016Äê4ÔÂ1ÈÕ¿ªÊ¼ÉúЧ¡£Í¨Ôò±êÌâÈçÏ£º The Mesilate Working Party which has been appointed in 2008 by the European Pharmacopoeia Commission has elaborated five General Chapters on different sulfonates which have been published in the European Pharmacopoeia Supplement 8.7 that came into force on 1 April 2016. The General Chapters are as follows: 2.5.37¼×»ÇËáÖеļ׻ù¡¢ÒÒ»ùºÍÒì±û»ù¼×»ÇËáõ¥£¨Methyl, ethyl and isopropyl methanesulfonate in methanesulfonic acid£© 2.5.38ÔÁÏÒ©Öеļ׻ù¡¢ÒÒ»ùºÍÒì±û»ù¼×»ÇËáõ¥£¨Methyl, ethyl and isopropyl methanesulfonate in active substances£© 2.5.39¼×»ÇËáÖеļ׻Çõ£ÂÈ£¨Methanesulfonyl chloride in methanesulfonic acid£© 2.5.40ÔÁÏÒ©Öеļ׻ù¡¢ÒÒ»ùºÍÒì±û»ù¼×±½»ÇËáõ¥£¨Methyl, ethyl and isopropyl toluenesulfonate in active substances£© 2.5.41ÔÁÏÒ©Öеļ׻ù¡¢ÒÒ»ùºÍÒì±û»ù±½»ÇËáõ¥£¨Methyl, ethyl and isopropyl benzenesulfonate in active substances£© 2016Äê2ÔÂ25ÈÕEDQM±¨µÀ£¬Å·ÃËÒ©µäίԱ»á¼×»ÇËáÑι¤×÷×éÍê³É2.5.41Õ£¬±êÖ¾×Ź¤×÷×éµÄ¹¤×÷½áÊø¡£Í¬Ê±£¬Î¯Ô±»á»¹¾ö¶¨ÐÞ¶©ÔÁÏÒ©-»ÇËáÑθ÷ÂÛÖеġ±Éú²ú¡°²¿·Ö£¬²ÉÓÃÁíÒ»·Ý±ê×¼ÎļþÀ´Ìæ´ú¡£¸ù¾Ý´Ë±ê×¼Îļþ£¬ÔÚÔÁÏÒ©Éú²úÖжԻùÒò¶¾ÐÔÔÓÖÊÓ¦½øÐзçÏÕ¹ÜÀí¡£Îı¾ÈçÏ£º As reported in a press release from the EDQM dated 25 February 2016 the completion of Chapter 2.5.41 marks the end of the Mesilate Working Party, as decided by the Ph. Eur. Commission. Simultaneously, the Commission had also decided to revise the section "Production" in APIs-Sulfonates monographs and replace it by an additional standard text according to which the principles of risk management have to be used in the manufacture of APIs with regard to the genotoxic impurities. The text is as follows: ¡°¡¾xxxõ¥¡¿¾ßÓлùÒò¶¾ÐÔ£¬¶øÇÒÊÇ¡¾xxÔÁÏÒ©¡¿µÄDZÔÚÔÓÖÊ¡£Éú²ú¹ý³ÌÖÐÓ¦¿¼ÂÇÖÊÁ¿·çÏÕ¹ÜÀíÔÔò£¬Í¬Ê±¿¼ÂÇÆðʼÎïÁÏ¡¢¹¤ÒÕÄÜÁ¦ºÍÑéÖ¤¡£Í¨Ôò¡¾2.5.XX¡¿¿ÉÒÔÓÃÀ´°ïÖúÉú²úÉÌ¡£¡± ¡°It is considered that [XXX esters] are genotoxic and are potential impurities in [name of the API]. The manufacturing process should be developed taking into consideration the principles of quality risk management, together with considerations of the quality of starting materials, process capability and validation. The general method [2.5.XX] is available to assist manufacturers." EPͨÔòÒ»°ãÀ´ËµÖ»Óе±ËüÃÇÔÚ¸÷ÂÛÖб»ÒýÓÃʱ¾ßÓÐÔ¼ÊøÁ¦£¬Î¨Ò»µÄÀýÍâÊǵ±Ö»ÊÇ×÷Ϊ²Î¿¼Ê±Îª½¨Òé¡£ÕâÊÊÓÃÓÚÉÏÊöÎå¸öͨÔò¡£ÔÚ¡°Éú²ú¡±²¿·ÖµÄÐÂÎļþÄÚÈÝ£¬Ä¿µÄÊǾ¯Ê¾ÉÏÊÐÐí¿ÉµÄÉêÇëÈË´ËÀà»ÇËáÔÓÖÊÏà¹ØµÄ·çÏÕ¡£²¢Ã»ÓÐÇ¿ÖÆÉ걨ÈËʵʩͨÔòÖÐËùÊöµÄ·ÖÎö²âÊÔ£¬µ«ÐèÒªÔÚÉ걨ÎļþÖвÉÓ÷çÏÕÆÀ¹ÀµÄ·½Ê½³ä·ÖÂÛÖ¤ÕâЩÔÓÖʲ»»á´æÔÚ¡£×îÖÕ¾ö¶¨ÕâЩÂÛÖ¤ÊÇ·ñ³ä·ÖÊÇÒ©¼àµ±¾ÖµÄÆÀ¹À¡£ Basically, the General Chapters of the European Pharmacopoeia will only be binding when they are referred to in a monograph; the only exception is when the reference made has only a recommendation character. This applies to all these five General Chapters. The purpose of the new text segment in the "Production" sections is to alert the applicant of a marketing authorisation of the risk related to such sulfonates impurities. He / she is not obliged to perform the analytical testing described in the general monographs; it is rather sufficient to strongly justify the absence of these impurities by means of a risk assessment in the application. The ultimate decision whether this justification is suffiicient lies with the assessor of the competent authority. |
» ±¾ÌûÒÑ»ñµÃµÄºì»¨£¨×îÐÂ10¶ä£©
» ²ÂÄãϲ»¶
Ò»Ö¾Ô¸ÌìÖÐÒ½ÖÐҩѧר˶£¬Ï£ÍûÓÐbÇøµÄÀÏʦ¿ÉÒÔ¿¼ÂÇÒ»ÏÂÎÒ
ÒѾÓÐ1È˻ظ´
µ÷¼Á
ÒѾÓÐ3È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ140È˻ظ´
ҩѧѧ˶326Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
26Ä격ʿÉêÇë
ÒѾÓÐ20È˻ظ´
½Î÷¿Æ¼¼Ê¦·¶´óѧ΢ÉúÎïÌìȻҩÎïÀÏʦ½éÉÜ
ÒѾÓÐ23È˻ظ´
ÇóÖú ±½Á×Áò°·JP
ÒѾÓÐ0È˻ظ´
100½ð±Ò °¢ÄªÎ÷ÁÖ¿ËÀάËá¼ØÆ¬BPÒ©µäÖÐÌáµ½µÄ¿ËÀάËá¾ÛºÏÎï¾ßÌå½á¹¹Ê½ÊÇɶ£¿
ÒѾÓÐ2È˻ظ´
ÉÅʳ²¹³ä¼ÁºÏ¹æÐÔ½»Á÷
ÒѾÓÐ0È˻ظ´
Ò»Ö¾Ô¸Õã´óҩѧÇóµ÷¼Á
ÒѾÓÐ0È˻ظ´
¸ßθßѹ·´Ó¦ÇóÖú
ÒѾÓÐ2È˻ظ´
mouse103
ר¼Ò¹ËÎÊ (ÖøÃûдÊÖ)
- DRDEPI: 16
- Ó¦Öú: 218 (´óѧÉú)
- ¹ó±ö: 0.384
- ½ð±Ò: 1423.7
- É¢½ð: 2586
- ºì»¨: 171
- ɳ·¢: 1
- Ìû×Ó: 1626
- ÔÚÏß: 411.4Сʱ
- ³æºÅ: 466716
- ×¢²á: 2007-11-24
- רҵ: ºÏ³ÉÒ©Îﻯѧ
- ¹ÜϽ: ÉúÎïÒ½Ò©Çø
3Â¥2016-05-05 10:09:03
kinggbp
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 14 (СѧÉú)
- ½ð±Ò: 2438.3
- É¢½ð: 3
- ºì»¨: 2
- Ìû×Ó: 678
- ÔÚÏß: 132.6Сʱ
- ³æºÅ: 3321146
- ×¢²á: 2014-07-13
- ÐÔ±ð: GG
- רҵ: Ò©¼Áѧ

5Â¥2016-05-06 15:13:29
Ì«-Ñô-Óê
ľ³æ (ÕýʽдÊÖ)
Сľ³æ
- Ó¦Öú: 3 (Ó×¶ùÔ°)
- ½ð±Ò: 8275.5
- É¢½ð: 253
- ºì»¨: 3
- Ìû×Ó: 748
- ÔÚÏß: 160.3Сʱ
- ³æºÅ: 1094294
- ×¢²á: 2010-09-09
- ÐÔ±ð: GG
- רҵ: »¯¹¤ÈÈÁ¦Ñ§ºÍ»ù´¡Êý¾Ý

6Â¥2016-05-06 19:06:10
huama322
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 656.7
- É¢½ð: 10
- ºì»¨: 5
- Ìû×Ó: 106
- ÔÚÏß: 88.2Сʱ
- ³æºÅ: 930466
- ×¢²á: 2009-12-18
- רҵ: Ò©Îï·ÖÎö
8Â¥2016-06-01 08:51:00













»Ø¸´´ËÂ¥
Âþ»ÎÑÎÑ